9

Cyclic-di-GMP diammonium

9 Publications Verification

Cat. No.: HY-107780B

CAS No.: 609343-82-0

Purity: 99.07%

Synonyms: c-di-GMP diammonium; cyclic diguanylate diammonium; 5GP-5GP diammonium

Category:

Natural Products Metabolic Disease Endogenous metabolite Disease Research Fields

Target:

STING Endogenous Metabolite

Cyclic-di-GMP diammonium is a STING agonist and a bacterial second messenger that coordinates different aspects of bacterial growth and behavior, including motility, virulence, biofilm formation, and cell cycle progression. Cyclic-di-GMP diammonium has anti-cancer cell proliferation activity and also induces elevated CD4 receptor expression and cell cycle arrest. Cyclic-di-GMP diammonium can be used in cancer research .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

9

Cyclic-di-GMP disodium

9 Publications Verification

Cat. No.: HY-110382

CAS No.: 2222132-40-1

Purity: 98.78%

Synonyms: c-di-GMP disodium; cyclic diguanylate disodium; 5GP-5GP disodium

Category:

Natural Products Endogenous metabolite Disease Research Fields Cancer

Target:

STING Endogenous Metabolite

Cyclic-di-GMP disodium is a STING agonist and a bacterial second messenger that coordinates different aspects of bacterial growth and behavior, including motility, virulence, biofilm formation, and cell cycle progression. Cyclic-di-GMP disodium has anti-cancer cell proliferation activity and also induces elevated CD4 receptor expression and cell cycle arrest. Cyclic-di-GMP disodium can be used in cancer research .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

7

Temsavir

7 Cited Publications

Cat. No.: HY-15440

CAS No.: 701213-36-7

Purity: 98.70%

Synonyms: BMS-626529

Target:

HIV

Research Areas:

Infection

Temsavir (BMS-626529) is a novel attachment inhibitor that targets HIV-1 gp120 and prevents its binding to CD4 ⁺ T cells.

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

7

Y-320

7 Cited Publications

Cat. No.: HY-15898

CAS No.: 288250-47-5

Purity: 99.03%

Target:

Interleukin Related Apoptosis

Research Areas:

Inflammation/Immunology Cancer

Y-320 is a potent, orally active phenylpyrazoleanilide immunomodulator. Y-320 inhibits IL-17 production by CD4 T cells stimulated with IL-15 with IC₅₀ values of 20 to 60 nM. Y-320 enhances TP53, DMD, and COL17A1 PTC readthrough by G418 and increases cellular protein levels and protein synthesis. Y-320 concomitants use of with a low dose of Paclitaxel (HY-B0015) significantly sensitized multidrug resistance (MDR) tumors by inducing G2/M phase arrest and apoptosis. Y-320 can be used for research of rheumatoid arthritis (RA) and cancer .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

6

AS2863619

6 Cited Publications

Cat. No.: HY-126675A

CAS No.: 2241300-51-4

Purity: 99.94%

Target:

STAT CDK Apoptosis TGF-beta/Smad

Research Areas:

Inflammation/Immunology

AS2863619 is an orally active CDK8/19 inhibitor that also inhibits BMP2, MDA5 and RIG-I receptors. AS2863619 targets Stat5a-CDK8/19 to promote the differentiation of CD4 ⁺ T cells into regulatory T cells and induce FOXP3 expression, thereby restoring immune homeostasis and establishing transplant immune tolerance. AS2863619 also enhances the BMP2/SMAD signaling pathway to promote osteogenic differentiation and inhibit adipogenic differentiation. AS2863619 exerts osteoprotective effects by alleviating inflammation-induced impairment of osteogenic function and inducing neutrophil apoptosis (apoptosis). AS2863619 can be applied to research in related fields such as periodontitis-induced bone defects .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

6

AS2863619 free base

6 Cited Publications

Cat. No.: HY-126675

CAS No.: 2241300-50-3

Purity: 99.68%

Target:

CDK TGF-beta/Smad Apoptosis STAT

Research Areas:

Inflammation/Immunology

AS2863619 free base is an orally active CDK8/19 inhibitor that also inhibits BMP2, MDA5 and RIG-I receptors. AS2863619 free base targets Stat5a-CDK8/19 to promote the differentiation of CD4 ⁺ T cells into regulatory T cells and induce FOXP3 expression, thereby restoring immune homeostasis and establishing transplant immune tolerance. AS2863619 free base also enhances the BMP2/SMAD signaling pathway to promote osteogenic differentiation and inhibit adipogenic differentiation. AS2863619 free base exerts osteoprotective effects by alleviating inflammation-induced impairment of osteogenic function and inducing neutrophil apoptosis (apoptosis). AS2863619 free base can be applied to research in related fields such as periodontitis-induced bone defects .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

5

Natalizumab

5 Cited Publications

Cat. No.: HY-108831

CAS No.: 189261-10-7

Purity: 99.10%

Natalizumab (AN100226; BG00002) is a humanized monoclonal IgG4 antibody inhibitor that selectively targets α4 integrin (CD49d). It blocks the interaction of integrins such as α4β1 (VLA-4) with vascular cell adhesion molecule VCAM-1, intercellular adhesion molecule ICAM-1, and fibronectin by competitively binding to the α4 subunit. Natalizumab inhibits the adhesion, retention, and transendothelial migration of immune cells (such as CD4 ⁺ T cells), reducing the infiltration of inflammatory cells into the central nervous system or lesion sites, thus exerting anti-inflammatory and immunomodulatory activity. Natalizumab is used in the study of relapsing-remitting multiple sclerosis (RRMS) and also has applications in the study of autoimmune or inflammation-related diseases such as Crohn's disease, B-cell lymphoma, and non-infectious uveitis. Natalizumab can also prevent lymphocytes from entering the central nervous system, thereby preventing acute demyelinating relapses .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

5

Natalizumab (Anti-CD49d)

5 Cited Publications

Cat. No.: HY-108831A

CAS No.: 189261-10-7

Purity: 98.72%

Synonyms: AN100226; BG00002

Natalizumab (Anti-CD49d) (AN100226; BG00002) Solution is a humanized monoclonal IgG4 antibody inhibitor that selectively targets α4 integrin (CD49d), blocking the interaction of integrins such as α4β1 (VLA-4) with vascular cell adhesion molecule VCAM-1, intercellular adhesion molecule ICAM-1, and fibronectin by competitively binding to the α4 subunit. Natalizumab solution inhibits the adhesion, retention, and transendothelial migration of immune cells (such as CD4 ⁺ T cells), reducing the infiltration of inflammatory cells into the central nervous system or lesion sites, thereby exerting anti-inflammatory and immunomodulatory activity. Natalizumab (Anti-CD49d) solution is used in the study of relapsing-remitting multiple sclerosis (RRMS) and is also applied in the research of autoimmune or inflammation-related diseases such as Crohn's disease, B-cell lymphoma, and non-infectious uveitis. Natalizumab (Anti-CD49d) can also prevent lymphocytes from entering the central nervous system, thus preventing acute demyelinating relapses .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

3

Fostemsavir

3 Cited Publications

Cat. No.: HY-15440A

CAS No.: 864953-29-7

Purity: 99.52%

Synonyms: BMS-663068

Target:

HIV

Research Areas:

Infection

Fostemsavir (BMS-663068) is the phosphonooxymethyl prodrug of BMS-626529. Fostemsavir (BMS-663068) is a novel attachment inhibitor that targets HIV-1 gp120 and prevents its binding to CD4 ⁺ T cells.

Compare

loading...